Free tool
FAERS Monitor: Solu-Medrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011856 or its brand name (Solu-Medrol, Methylprednisolone Sodium Succinate). Reports on generic versions are filed under their own applications.
Reports
46,927
Serious
41,904
89% of reports
Hospitalization
20,309
Death reported
8,961
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use8,135
- drug ineffective4,495
- fatigue4,349
- headache4,161
- pain4,119
- infusion related reaction4,031
- nausea3,908
- pyrexia3,843
- dyspnoea3,716
- rash3,258
- arthralgia3,078
- diarrhoea3,046
- hypertension2,995
- pneumonia2,944
- vomiting2,894
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 620 |
| 2005 | 732 |
| 2006 | 630 |
| 2007 | 782 |
| 2008 | 777 |
| 2009 | 789 |
| 2010 | 995 |
| 2011 | 1,462 |
| 2012 | 1,369 |
| 2013 | 998 |
| 2014 | 1,379 |
| 2015 | 1,856 |
| 2016 | 1,889 |
| 2017 | 1,907 |
| 2018 | 2,094 |
| 2019 | 3,063 |
| 2020 | 3,755 |
| 2021 | 3,426 |
| 2022 | 4,111 |
| 2023 | 3,747 |
| 2024 | 4,357 |
| 2025 | 3,953 |
| 2026 | 2,231 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,232 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 4,031 | 29.0 | 28.1 | 102,481 |
| hypertensionSignal | 2,995 | 6.4 | 6.2 | 13,627 |
| pyrexiaSignal | 3,843 | 5.0 | 4.9 | 12,444 |
| off label useSignal | 8,135 | 4.2 | 4.1 | 20,450 |
| pneumoniaSignal | 2,944 | 4.1 | 4.0 | 6,952 |
| rashSignal | 3,258 | 3.4 | 3.3 | 5,494 |
| arthralgiaSignal | 3,078 | 3.3 | 3.2 | 5,094 |
| painSignal | 4,119 | 3.0 | 2.9 | 5,688 |
| headacheSignal | 4,161 | 3.0 | 2.9 | 5,632 |
| dyspnoeaSignal | 3,716 | 3.0 | 2.9 | 4,905 |
| vomitingSignal | 2,894 | 2.8 | 2.7 | 3,325 |
| fatigueSignal | 4,349 | 2.5 | 2.4 | 4,086 |
| nauseaSignal | 3,908 | 2.2 | 2.2 | 2,705 |
| diarrhoeaSignal | 3,046 | 2.1 | 2.0 | 1,850 |
| drug ineffective | 4,495 | 1.5 | 1.5 | 878 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.